KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Interest Expenses (2019 - 2025)

GoodRx Holdings' Interest Expenses history spans 7 years, with the latest figure at $10.4 million for Q4 2025.

  • For Q4 2025, Interest Expenses fell 8.41% year-over-year to $10.4 million; the TTM value through Dec 2025 reached $42.6 million, down 19.49%, while the annual FY2025 figure was $42.6 million, 19.49% down from the prior year.
  • Interest Expenses for Q4 2025 was $10.4 million at GoodRx Holdings, down from $10.8 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $14.8 million in Q4 2023 and bottomed at $5.9 million in Q1 2022.
  • The 5-year median for Interest Expenses is $10.8 million (2025), against an average of $10.5 million.
  • The largest annual shift saw Interest Expenses tumbled 31.64% in 2021 before it soared 123.77% in 2023.
  • A 5-year view of Interest Expenses shows it stood at $5.9 million in 2021, then soared by 102.05% to $11.9 million in 2022, then rose by 24.26% to $14.8 million in 2023, then fell by 23.37% to $11.4 million in 2024, then dropped by 8.41% to $10.4 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Interest Expenses are $10.4 million (Q4 2025), $10.8 million (Q3 2025), and $10.7 million (Q2 2025).